We Claim:

1. A combination comprising an antibody specific for CD19 wherein said antibody comprises an HCDR1 region comprising sequence SYVMH (SEQ ID NO: 1), an HCDR2 region comprising sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region comprising sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region comprising sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region comprising sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region comprising sequence MQHLEYPIT (SEQ ID NO: 6) and venetoclax for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

2. A combination according to claim 1, wherein the antibody has ADCC activity.

3. A combination according to claims 1 or 2, wherein the antibody comprises a variable heavy chain comprising the sequence
EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPY
NDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWG
QGTLVTVSS (SEQ ID NO: 10) and a variable light chain of the sequence
DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYR
MSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 11).

4. A combination according to any one of the preceding claims, wherein the antibody comprises a heavy chain constant domain comprising the sequence
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL
SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPK
DTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQD
WLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA
VEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL
SLSPGK (SEQ ID NO: 12).

5. A combination according to any one of the preceding claims, wherein the antibody comprises a light chain constant domain comprising the sequence
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC. (SEQ ID NO: 13)

6. A combination according to any one of the preceding claims, wherein said antibody specific for CD19 and venetoclax are administered separately.

7. A combination according to any one of the preceding claims, wherein venetoclax is administered prior to administration of the antibody specific for CD19.

8. A combination according to any one of the preceding claims, wherein said antibody specific for CD19 and venetoclax are administered simultaneously.

9. A combination according to any one of the preceding claims, wherein said antibody specific for CD19 and venetoclax are administered at a time where both drugs are active in the patient at the same time.

10. A combination according to any one of the preceding claims for use in the treatment of chronic lymphocytic leukemia.

11. A combination according to any one of the preceding claims for use in the treatment of acute lymphoblastic leukemia.

12. A combination according to any one of the preceding claims for use in the treatment of non-Hodgkin’s lymphoma, wherein the non-Hodgkin’s lymphoma is selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid tissue, marginal zone, diffuse large B cell, Burkitt's, and mantle cell lymphoma.